Total number of patients | All patients | Newly diagnosed ICM | Newly diagnosed NICM | ICD explant | Newly diagnosed CMP |
---|---|---|---|---|---|
LVEF ≤ 35% | LVEF ≤ 35% | LVEF ≥ 35% | |||
n = 105 | n = 43 | n = 41 | n = 15 | n = 6 | |
Age, years, median (range) | 60 (26–79) | 62 (43–78) | 54 (30–78) | 62 (29–79) | 53 (26–63) |
Male sex, n (%) BMI kg/ m2, mean ± SD | 82 (78.1) 28.6 ± 6.6 | 35 (81.4) 28.2 ± 6.2 | 28 (68.3) 29.8 ± 7.1 | 14 (93.3) 28.7 ± 6.7 | 5 (83.3) 23.5 ± 3.6 |
Arrhythmias before WCD | |||||
Atrial flutter or fibrillation, n (%) | 34 (32.4) | 10 (23.3) | 15 (36.6) | 8 (53.3) | 1 (16.7) |
Previous VT/VF/SCD, n (%) | 21 (20.0) | 6 (14.0) | 2 (4.9) | 8 (53.3) | 5 (83.3) |
Conduction Disorders | |||||
LBBB, n (%) | 19 (18.1) | 3 (7.0) | 10 (24.4) | 6 (40.0) | 0 (0) |
Cardiovascular risk factors | |||||
Diabetes, n (%) | 29 (27.6) | 14 (32.6) | 10 (24.4) | 4 (26.7) | 1 (16.7) |
Hypertension, n (%) | 71 (67.6) | 38 (88.4) | 16 (6.6) | 13 (86.7) | 4 (66.6) |
Hyperlipidemia, n (%) | 62 (59.0) | 31 (72.1) | 17 (41.5) | 12 (80.0) | 2 (33.3) |
Concomitant diseases | |||||
Kidney Dysfunction, n (%) | 20 (19.0) | 10 (23.3) | 6 (14.6) | 3 (20.0) | 1 (16.7) |
COPD, n (%) | 9 (8.6) | 3 (7.0) | 3 (7.3) | 2 (13.3) | 1 (16.7) |
NYHA, mean ± SD | 2.7 ± 1.2 | 2.7 ± 1.3 | 3.0 ± 1.0 | 2.5 ± 0.9 | 1.3 ± 0.5 |
LVEF baseline, mean % ± SD | 28.3 ± 9.8 | 28.9 ± 6.0 | 23.3 ± 6.9 | 32.2 ± 13.3 | 49.0 ± 7.5 |
Medication | |||||
Betablocker, n (%) | 102 (97.1) | 41 (95.3) | 40 (97.6) | 15 (100.0) | 6 (100.0) |
ACE-I/ARB, n (%) | 97 (92.4) | 42 (97.7) | 39 (95.1) | 11 (73.3) | 5 (83.3) |
MRA, n (%) | 67 (63.8) | 25 (58.1) | 35 (85.4) | 5 (33.3) | 2 (33.3) |
ARNI, n (%) | 1 (1.0) | 0 (0) | 1 (2.4) | 0 (0) | 0 (0) |
Procoralan, n (%) | 6 (5.7) | 0 (0) | 5 (12.2) | 1 (6.7) | 0 (0) |
Diuretic, n (%) | 71 (67.6) | 26 (60.5) | 31 (75.6) | 12 (80.0) | 2 (33.3) |
Amiodarone, n (%) | 12 (11.4) | 1 (2.3) | 5 (12.2) | 6 (40.0) | 0 (0) |